Non-Hormonal Hot Flash Treatment: Lynkuet vs Veozah

By Kevin Wolfe, Founder & CEO

Reviewed by Kindr Health Clinical Team

Published November 9, 2026 · Updated November 9, 2026

If hormones aren't an option for you, or you'd rather not use them, two of the newer FDA-approved nonhormonal prescription options for hot flashes are fezolinetant (Veozah) and elinzanetant (Lynkuet) (a low-dose form of paroxetine is also FDA-approved for moderate to severe menopausal hot flashes). Veozah and Lynkuet are prescription pills for moderate to severe hot flashes caused by menopause, and both work on brain pathways involved in temperature control rather than on hormones. They aren't interchangeable, and no study has compared them head to head. Here's how they differ, what their labels say about risks, and what to ask your clinician.

For a shorter site FAQ on the same comparison, see Elinzanetant vs fezolinetant on our FAQ. Related Kindr pages: Veozah vs HRT, fezolinetant vs HRT, and hot flashes and night sweats.

Non-hormonal hot flash treatment: what's FDA-approved now

Three prescription medicines are FDA-approved for moderate to severe vasomotor symptoms (hot flashes) due to menopause without using estrogen:

1. Low-dose paroxetine mesylate 7.5 mg (Brisdelle) — an SSRI approved for moderate to severe VMS associated with menopause (not for psychiatric conditions at this dose).
2. Fezolinetant (Veozah) — a neurokinin-3 (NK3) receptor antagonist.
3. Elinzanetant (Lynkuet) — a neurokinin-1 (NK1) and neurokinin-3 (NK3) receptor antagonist.

This post focuses on the two newer neurokinin-receptor options, Veozah and Lynkuet. Neither contains hormones. "FDA-approved" here means approved for that hot-flash indication—not a ranking, and not a claim that Kindr prescribes either drug. Naming a medicine does not mean Kindr Health supplies it or that it is right for you.

Brisdelle has its own boxed warning (suicidal thoughts and behaviors, as with other SSRIs) and other important risks; if your clinician is considering it, read its prescribing information and discuss it directly. The rest of this article does not compare Brisdelle head to head with Veozah or Lynkuet.

How the two pills work

Both Veozah and Lynkuet act on kisspeptin/neurokinin B/dynorphin (KNDy) pathways in the brain's thermoregulatory center—the system involved in hot flashes—rather than replacing estrogen.

• Fezolinetant (Veozah) blocks the NK3 receptor.
• Elinzanetant (Lynkuet) blocks both the NK1 and NK3 receptors.

That mechanistic difference is why people often ask which is "better." Labels and trials do not answer that as a head-to-head contest. Different receptor targets do not, by themselves, prove one drug works better for you.

What the evidence does and doesn't show

Each medicine was studied against placebo for moderate to severe menopausal hot flashes. No randomized head-to-head trial has compared Lynkuet directly with Veozah, so current evidence cannot say that one works better than the other for hot flashes.

A 2026 systematic review and meta-analysis in Menopause (PubMed 42837121) pooled seven randomized trials with 3,184 women and looked at self-reported sleep disturbance (PROMIS Sleep Disturbance Short Form 8b) at 4, 12, and 24 weeks. Neurokinin-receptor antagonists were associated with improved sleep scores versus placebo at those time points. The authors rated the certainty of evidence as low because of substantial unexplained heterogeneity. It is not a head-to-head trial of Lynkuet versus Veozah.

Sleep improvement in people with hot flashes is also not the same as proving a drug treats insomnia on its own, and it does not replace reading each label's risks.

Risks to know

Both medicines have important safety monitoring. The summaries below are matched to the current DailyMed labels and are given equal prominence. They are not complete prescribing information. Always read the full label and talk with your clinician about your history and other medicines.

Veozah (fezolinetant)

Veozah has a boxed warning for serious liver injury (hepatotoxicity). Your clinician will order liver blood tests before you start, monthly for the first 3 months, and again at 6 and 9 months. Stop Veozah and call your clinician right away if you have signs of liver problems such as new tiredness, loss of appetite, nausea, vomiting, itching, yellowing of the skin or eyes, pale stools, dark urine, or abdominal pain. Veozah should not be used by people with cirrhosis, severe kidney impairment or end-stage kidney disease, or with medicines that are CYP1A2 inhibitors. Read the full Veozah prescribing information and ask your clinician about other medicines you take.

Lynkuet (elinzanetant)

Lynkuet's label includes a warning about seizures; use caution if you have a history of seizures or conditions that lower the seizure threshold. It is contraindicated in pregnancy and may cause pregnancy loss or stillbirth; women who could become pregnant need pregnancy excluded before starting and effective contraception during treatment and for 2 weeks after the last dose. It can cause sleepiness and other nervous-system effects—avoid driving or hazardous activities until you know how it affects you. Liver blood tests are required before starting and at 3 months; stop and call your clinician for signs of liver injury (same symptom list as above). It isn't recommended for people with moderate or severe liver impairment or end-stage kidney disease. Ask your clinician about other medicines you take: avoid strong CYP3A4 inhibitors and grapefruit juice; moderate CYP3A4 inhibitors may require a lower Lynkuet dose; avoid strong or moderate CYP3A4 inducers. Read the full Lynkuet prescribing information.

"Nonhormonal" does not mean "no monitoring."

What to ask your clinician

Bring a short list so the visit stays concrete:

• Are hormones an option for me, or are we focusing on nonhormonal care because of my history or preference?
• Between Veozah, Lynkuet, low-dose paroxetine, and other options, which fit my liver/kidney history, seizure risk, pregnancy potential, and other medicines?
• What blood tests and follow-up does this medicine require, and what symptoms mean I should stop and call?
• How will we judge whether it's helping my hot flashes—and my sleep—over the next few weeks?

Other nonhormonal options (ACOG, October 2026). ACOG's October 2026 guidance reviews nonhormonal pharmacologic choices that include SSRIs/SNRIs and neurokinin-receptor antagonists such as fezolinetant and elinzanetant. Low-dose paroxetine is the antidepressant FDA-approved for VMS. ACOG also discusses nonpharmacologic approaches—cognitive behavioral therapy, mindfulness-based interventions, exercise, clinical hypnosis, and acupuncture—often as adjuncts alongside medication. ACOG states that evidence does not support the safety or efficacy of phytoestrogens or herbal supplements for these symptoms.

Hormone therapy remains an important option for many people with menopause symptoms when it is appropriate. Hormone therapy isn't right for everyone: depending on age, timing, health history and the type used, it can raise the risk of blood clots, stroke and breast cancer, and estrogen without a progestogen raises the risk of uterine cancer in people who have a uterus. If HT is chosen, ACOG recommends shared decision-making and, when selected without contraindications, starting before age 60 or within 10 years of spontaneous menopause—timing for symptom care, not a prevention claim.

Naming Veozah, Lynkuet, or Brisdelle here does not mean Kindr Health prescribes them. Treatment options vary by state and clinical eligibility. A clinician decides based on your health history.

Where Kindr fits

If you're weighing hormone and non-hormone options, when enrollment opens Kindr's board-certified clinicians can talk through what may fit you. Join the waitlist at kindr.health.

This article is for educational purposes only and is not medical advice. Talk with your clinician before starting, stopping or changing any medication. See our medical disclaimer.

Medically reviewed by Kindr Health Clinical Team
Last updated: November 9, 2026